|
|
CEM/C2
|
|
|
WG Harker |
|
Biosafety Level: |
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
suspension |
|
|
Homo sapiens (human)
|
|
|
lymphoblast
|
|
|
Organ: peripheral blood Disease: acute lymphoblastic leukemia Cell Type: T lymphoblast; |
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
Amelogenin: X CSF1PO: 11 D13S317: 11,12 D16S539: 10,13 D5S818: 13 D7S820: 9,8.3 THO1: 6,7 TPOX: 8 vWA: 17,19 |
|
|
4 years |
|
|
female |
|
|
Caucasian |
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0°C |
|
|
Protocol: Cultures can be maintained by addition or replacement of medium. Establish new cultures at 2 X 10 exp5 viable cells/ml and maintain between 1 X 10 exp5 and 2 X 10 exp6. Medium Renewal: Every 2 to 3 days |
|
|
Freeze medium: Complete growth medium 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor temperature |
|
|
30 hrs |
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001 recommended serum:ATCC 30-2020 parental cell line:ATCC CCL-119 |
|
|
22339: Kapoor R, et al. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res. 7: 83-95, 1995. PubMed: 7579731 23117: Fujimori A, et al. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 55: 1339-1346, 1995. PubMed: 7882333 |